JP2024544538A - THR-βアゴニストによる肝障害の治療 - Google Patents

THR-βアゴニストによる肝障害の治療 Download PDF

Info

Publication number
JP2024544538A
JP2024544538A JP2024527603A JP2024527603A JP2024544538A JP 2024544538 A JP2024544538 A JP 2024544538A JP 2024527603 A JP2024527603 A JP 2024527603A JP 2024527603 A JP2024527603 A JP 2024527603A JP 2024544538 A JP2024544538 A JP 2024544538A
Authority
JP
Japan
Prior art keywords
compound
pharma
acceptable salt
dose
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544538A5 (cg-RX-API-DMAC7.html
Inventor
ティ ジョーンズ,クリストファー
クルーチャー,ケビン
バリー クリッテンデン,ディー
ケイ クワーク,エリン
ジン,フォン
ドゥアン,マット
グオ,シェン
ビアン,ジャンウェイ
ドォン,チェンチェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of JP2024544538A publication Critical patent/JP2024544538A/ja
Publication of JP2024544538A5 publication Critical patent/JP2024544538A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
JP2024527603A 2021-11-11 2022-11-11 THR-βアゴニストによる肝障害の治療 Pending JP2024544538A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021130083 2021-11-11
CNPCT/CN2021/130083 2021-11-11
CNPCT/CN2022/097426 2022-06-07
CN2022097426 2022-06-07
PCT/CN2022/131297 WO2023083288A1 (en) 2021-11-11 2022-11-11 TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST

Publications (2)

Publication Number Publication Date
JP2024544538A true JP2024544538A (ja) 2024-12-03
JP2024544538A5 JP2024544538A5 (cg-RX-API-DMAC7.html) 2025-11-18

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527603A Pending JP2024544538A (ja) 2021-11-11 2022-11-11 THR-βアゴニストによる肝障害の治療

Country Status (14)

Country Link
US (1) US20240293416A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429666A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544538A (cg-RX-API-DMAC7.html)
KR (1) KR20240101642A (cg-RX-API-DMAC7.html)
CN (1) CN118871113A (cg-RX-API-DMAC7.html)
AU (1) AU2022388507A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238108A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007225A2 (cg-RX-API-DMAC7.html)
IL (1) IL312637A (cg-RX-API-DMAC7.html)
MX (1) MX2024005647A (cg-RX-API-DMAC7.html)
PE (1) PE20241327A1 (cg-RX-API-DMAC7.html)
TW (1) TW202332447A (cg-RX-API-DMAC7.html)
WO (1) WO2023083288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
CN121081472A (zh) * 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
WO2021231646A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
CL2024001399A1 (es) 2024-11-08
CN118871113A (zh) 2024-10-29
TW202332447A (zh) 2023-08-16
WO2023083288A1 (en) 2023-05-19
CA3238108A1 (en) 2023-05-19
EP4429666A1 (en) 2024-09-18
PE20241327A1 (es) 2024-06-26
AU2022388507A1 (en) 2024-06-20
KR20240101642A (ko) 2024-07-02
MX2024005647A (es) 2024-05-24
IL312637A (en) 2024-07-01
US20240293416A1 (en) 2024-09-05
EP4429666A4 (en) 2025-12-24
CO2024007225A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
WO2023083288A1 (en) TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
TWI663975B (zh) 治療肝臟疾病之方法
US20230241071A1 (en) Combination treatment of liver disorders
JP2024112818A (ja) 肝臓病
TWI667025B (zh) 治療肝臟疾病之方法
TW202207928A (zh) 肝病之組合治療
CN113908158A (zh) 使用fxr激动剂的方法
JP2024543419A (ja) Ssao阻害剤による肝障害の治療
US11517540B2 (en) Restoring physiology in iron-deficient organisms using small molecules
JP7756126B2 (ja) 脂肪性肝疾患の治療薬
CN1145482C (zh) 泛喹酮在治疗阿尔茨海默氏病中的用途
KR20150092742A (ko) 콜레스테롤 흡수 억제제와의 조합으로 글루카곤 수용체 길항제를 투여함으로써 당뇨병을 치료하는 방법
US20250120981A1 (en) Mrtx1133 pharmaceutical compositions
US12564600B2 (en) System for enhancing therapeutic compliance of the anti-cancer compound E7766
HK40118289A (en) TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
US20240165093A1 (en) Methods for treating familial chylomicronemia syndrome
US20070191324A1 (en) Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
RU2849641C1 (ru) Терапевтическое средство против жировой болезни печени
RU2857392C2 (ru) Способы лечения синдрома семейной хиломикронемии
HK40113179A (en) Treatment with ileal bile acid transporter (ibat) inhibitors for increased event-free survival (efs)
HK40129994A (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
HK40080642A (zh) 脂肪性肝病的治疗药

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251110